India-based global pharma making generics, biosimilars, vaccines, APIs and consumer wellness products
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 102 | 102 | 102 | 101 | 101 | 101 | 101 | 101 |
| Reserves | 10.3k | 12.9k | 16.9k | 17.4k | 19.7k | 23.9k | 25.2k | 27.0k |
| Borrowings | 8.0k | 4.6k | 4.2k | 1.2k | 804 | 3.2k | 9.6k | 12.5k |
| Other Liabilities | 5.1k | 6.2k | 6.4k | 6.9k | 8.2k | 9.5k | 12.0k | 11.1k |
| Total Liabilities | 23.5k | 23.8k | 27.6k | 25.6k | 28.8k | 36.7k | 46.9k | 50.7k |
| AssetsFixed Assets | 12.2k | 12.1k | 12.3k | 11.5k | 12.4k | 13.1k | 23.1k | 24.1k |
| CWIP | 742 | 783 | 661 | 1.2k | 2.4k | 2.7k | 1.2k | 3.7k |
| Investments | 765 | 830 | 3.3k | 1.5k | 1.2k | 6.4k | 5.9k | 7.5k |
| Other Assets | 9.7k | 10.0k | 11.4k | 11.3k | 12.8k | 14.5k | 16.8k | 15.3k |
| Total Assets | 23.5k | 23.8k | 27.6k | 25.6k | 28.8k | 36.7k | 46.9k | 50.7k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 1.3k | 2.5k | 3.3k | 2.1k | 2.7k | 3.2k | 6.8k | 2.1k |
| Cash from Investing | -4.0k | -1.0k | -835 | 1.1k | 1.2k | -1.5k | -8.4k | -7.9k |
| Cash from Financing | 1.9k | -1.1k | -2.5k | -868 | -4.4k | -1.8k | 2.0k | 5.8k |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 236 | 1.6k | 2.4k | 1.1k | 1.7k | 2.3k | 5.1k | -530 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (22.2×) and current (21.4×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 34.8% growth and a 21× exit, ₹1071 only delivers your return if you pay ₹2,247. The price is currently baking in 18% growth.
EPS grows 34.8%/yr for 5 years, then fades to 6% over 2, exits at 21×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 34.8% | 67.53 |
| FY28 | 34.8% | 91.04 |
| FY29 | 34.8% | 122.72 |
| FY30 | 34.8% | 165.42 |
| FY31 | 34.8% | 222.99 |
| FY32 | 20.4% ·fade | 268.48 |
| FY33 | 6.0% ·fade | 284.59 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.